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Abstract 
Over the past 20 years, huge advances have been made in modelling human diseases such as 
cancer using genetically modified mice. Accurate in vivo models are essential to examine the complex 
interaction between cancer cells, surrounding stromal cells, tumour associated inflammatory cells, 
fibroblast and blood vessels, and to recapitulate all the steps involved in metastasis. Elucidating these 
interactions in vitro has inherent limitations, and thus animal models are a powerful tool to enable 
researchers to gain insight into the complex interactions between signalling pathways and different 
cells types. This review will focus on how advances in in vivo models have shed light on many 
aspects of cancer biology including the identification of oncogenes, tumour suppressors and stem 
cells, epigenetics, cell death and context dependent cell signalling. 
Summary 
This review highlights the achievements of the late Professor Alan Clarke in developing the first knockout 
mice and sets his work in the general context of the scientific field he contributed to, namely using mouse 
models to understand cancer biology. 
Introduction  
The discovery of mutated genes in tumours spawned a whole new field of science, dedicated to 
understanding the link between genetics and cancer. In 1953, Carl Nordling hypothesised that cancer 
was caused by the accumulation of mutations over time (1), and this theory was further supported by 
analysis of retinoblastoma patients by Alfred Knudson in 1971. Knudson observed that inherited 
retinoblastoma developed in both eyes of children, whilst sporadic retinoblastoma developed in older 
patients and usually only in one eye (2).  He correctly hypothesised that retinoblastoma in young 
patients was due to inheritance of a single mutation, later identified to be in the Retinoblastoma-1 
(RB1) gene, however pathology would only occur if a second mutation occurred in a somatic cell. 
Nordling and Knudson did not have the genetic tools to functionally demonstrate that their theories 
were correct, but researchers were working hard to develop the ability to introduce a mutation into a 
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gene and thus study its requirement in development and disease. Sir Martin Evans took the first steps 
towards this goal in 1981, by developing a method to culture pluripotent stem cells from mouse 
embryos (3). This was the precursor which subsequently allowed Oliver Smithies and Mario Capecchi 
to modify cultured embryonic stem cells using homologous recombination to specifically target the 
HPRT gene (4,5). Two years later this technology was used to correct the mutant HPRT gene and 
generate the first targeted, genetically modified mouse which passed on the modified gene to its 
progeny via the germ line (6). 
Rb1 was the first tumour suppressor knocked out in mice using gene targeting and was published by 
three groups in the same issue of Nature in 1992 (7-9). However, these mice did not develop 
retinoblastoma until compound mutant mice were generated which had a mutation in Rb1 and its 
family member p107 (10). It has since been observed that Rb1 mutations deregulate the cell cycle in 
several different cancers and that Rb1 interacts with other tumour suppressor genes such as p53 
(11). 
From these pioneering works, which resulted in the Nobel Prize in 2007 for Sir Martin Evans, Oliver 
Smithies and Mario Capecchi, researchers have been given the tools to study the function of genes in 
vivo and these tools has subsequently developed into more sophisticated and precise ways of 
manipulating genes to yield fundamental advances in many fields of biology. Among these 
discoveries have been the generation of increasingly accurate mouse models of disease, the 
identification of stem cells in various tissues and genetic evidence of the interaction between different 
gene products. This review will focus on some of the extraordinary advances in the fields of cell 
signalling (and particularly Wnt signalling), apoptosis and stem cells in the intestine, and how these 
findings have increased our understanding of intestinal cancer, and led to novel therapeutic 
strategies.  
 
 
The origins of mouse models of epithelial cancer 
In a complementary approach to the gene targeting techniques described above, several groups were 
investigating the genetic events that resulted from exposure to carcinogens (reviewed in (12).  In 
1983, two groups identified that tumours induced by experimentally applied carcinogens were due to 
an activating mutation to the Harvey-ras (H-ras) oncogene (13) (14). These types of experiments were 
among the first to demonstrate that carcinogens could mutate specific genes to transform cells. 
Subsequently, William Dove’s treated mice with ethylnitrosourea, with the aim of identifying new 
tumour suppressor genes. They identified a pedigree of mice that developed multiple intestinal 
neoplasias throughout the length of the intestinal tract with 100% penetrance, and named this gene 
Min (Multiple intestinal neoplasia) (15). Although originally it was not known which gene was 
responsible for the tumourigenesis subsequent work showed the gene mutated was the APC 
(Adenomatous Polyposis coli) gene. This gene is the most commonly mutated gene in sporadic 
human colorectal cancer (CRC) and people who are germline heterozygous for APC, FAP (Familial 
Adenomatous Polyposis) patients are strongly predisposed to CRC. Thus this first mouse model of 
intestinal cancer would enable researchers to investigate the molecular events of intestinal 
tumourigenesis and growth in vivo.  Moreover, from a very early stage these mice were used to 
investigate potential chemopreventative agents such as aspirin (16) which have subsequently proved 
to have activity in humans (17). 
The ability to direct mutations into a selected gene in ESCs and generate mice from these cells has 
provided great insights into developmental biology and disease, specific examples of which are 
provided below. In addition to deletion of parts of genes, homologous recombination made it possible 
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to introduce the exact mutations found in human disease, which could sometimes hyperactive the 
gene product rather than delete it.  However, there are some limitations to what can be achieved 
using this approach. For example, about 15% of all knockout mice are embryonic lethal and therefore 
any role for the mutated gene in adults cannot be assessed. To overcome this, scientists began 
looking for ways to inducibly delete genes in adult somatic cells of mice. 
An important step toward this goal was the generation of transgenic mice. Superseding the generation 
of knockout mice, five groups independently demonstrated that they were able to successfully 
microinject oocytes with DNA constructs, which were then implanted into pseudo-pregnant recipient 
mice, to produce transgenic mice in which the introduced DNA was transmitted to progeny and 
retained expression (18-22). This type of transgenic mouse differs from the classical knockouts to 
mutate a specific gene, in that the introduced DNA is randomly integrated into the host DNA, but this 
technology has had an equally important impact on the study of genes in vivo. Indeed Jerry Adams 
and Suzanne Cory generated the first oncomouse by fusing an immunoglobulin enhancer (Eµ) to the 
Myc gene.  These mice developed pre-B-cell and mature B cell lymphomas and supported the 
hypothesis that the Ig-Myc translocations observed in patients were malignant events (23). 
Transgenic mice also provided the genetic tools for the ability to conditionally delete a gene in a 
specific tissue in adult somatic cells when used in combination with knockout mice.  
 
 
Inducible manipulation of genes in vivo 
Temporal regulation of eukaryotic promoters to manipulate gene expression proved unsuccessful. 
However, in 1992 Manfred Gossen and Hermann Bujard generated a tetracycline-controlled 
transactivator (tTA) by fusing the tet repressor element of E. coli to the activating domain of virion 
protein 16 of herpes simplex virus. Importantly, they then demonstrated that this construct worked in 
mammalian cells in vitro (24), and transgenic mice (25).  This technology was used to demonstrate an 
essential role for mutant H-Ras in tumour maintenance (26), and was more recently refined to allow 
temporal expression of shRNAs, which is proving to be a powerful research tool (27). 
The most widely used approach to conditionally manipulate genes in vivo is the Cre-LoxP (Causes 
recombination-Locus of crossover P1) system. Cre is a site-specific DNA recombinase used by 
bacteriophage P1 during viral genome replication and is not expressed in mammals. It recognises 
specific 34bp palindromic sequences of DNA, termed LoxP sites, and recombines the DNA between 
two LoxP sites, thus deleting it. In 1988 Sauer and Henderson demonstrated this system was able to 
work in mammalian cells, with the advantage that no mammalian protein is capable of recognising the 
lox sites (28), and in 1994 a T-cell-specific deletion of the DNA polymerase β gene was achieved in 
vivo (29). 
In addition to deletion of specific areas of DNA, Cre-Lox technology also allows for conditional 
activation of genes, by inserting a lox flanked stop codon into a gene. The subsequent Cre mediated 
removal of the stop codon then permits read-through and transcription of the gene (30). Regulation of 
Cre recombinase activity is most commonly achieved by use of a tissue-specific promoter, allowing 
spatial control of Cre expression. More recent versions of this technology have incorporated a 
secondary, temporal control of recombinase activity by fusing the Cre enzyme to a modified 
oestrogen receptor, allowing for activation of Cre only after administration of tamoxifen (TM). Several 
groups have demonstrated tissue-specific manipulation of gene activity by using transgenic Cre-ERTM 
mice (31-33), which was superseded by an improved version called Cre-ERT2 (34).  
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These types of experiments use a combination of transgenic mice to generate the Cre-expressing 
line, and knockin mice to generate the Lox-flanked alleles, thus bringing together the two technologies 
to enable the ability to conditionally manipulate genes.  More recently combining Cre-Lox technology 
with another system that allows conditional activation/deletions of alleles independently of tamoxifen 
exposure (FLP FRT), has allowed questions on tumour maintenance and/or the importance of stromal 
genes to be investigated as now tumours can be driven by one system and genes deleted by the 
other (35). Although the Cre-Lox system allows tissue specific, inducible manipulation of gene 
expression, presently the introduced genetic change cannot be reversed to interrogate questions on 
tumour maintenance. This however was achieved by refining of the tetracycline system, in which the 
tTA protein can only operate to activate transcription in the presence or absence of tetracycline, or a 
tetracycline derivative such as doxycycline. Thus, in the tet-Off system, tTA binds to a tetracycline-
responsive promoter element (TRE) and activates transcription of a downstream target gene, which is 
blocked by the presence of doxycycline. In the tet-On system the reverse tTA (rtTA) fusion protein can 
only recognise the TRE and activate transcription of the target gene in the presence of doxycycline. 
As the binding of tTA or rtTA to the TRE does not alter the genetic material itself this is a reversible 
mechanism of gene manipulation (36) which has now been used in mouse models for several 
decades. This system has allowed key oncogenes such as MYC and KRAS to be switched on and off 
and the mechanism of tumour regression investigated. With the development of conditional gene 
modification researchers now had very powerful tools in which they could investigate molecular cell 
biology in vivo, and the chapters below will highlight some of the important discoverers in intestinal 
biology and cancer using these technologies.  
 
 
Using mouse models to study intestinal carcinogenesis 
Interaction of oncogenes and tumour suppressor genes in intestinal cancer  
As mentioned above, two years after William Dove’s group had generated the Min mouse, the same 
group published that the gene mutated was homologous to a gene called adenomatous polyposis coli 
(APC), which was mutated in patients with FAP and sporadic intestinal tumours (37). FAP patients are 
born with a mutation in one allele of APC, and during adulthood a somatic mutation of the remaining 
wild-type allele triggers tumorigenesis, thus supporting the Knudsonian ‘two-hit’ hypothesis. At this 
early stage of the research, the function of the APC gene was unknown, however, during a screen for 
binding partners, β-catenin was identified as an interactor of APC (38).  β-catenin had already been 
identified as the mammalian homologue to the Drosophila gene armadillo, a component of the 
Wingless (Wnt) signalling pathway (39), and comprehensive in vitro experiments using a panel of Apc 
mutant proteins demonstrated that cells with mutant APC had activated β-catenin and the Wnt 
pathway (40,41). Thus the link had been made between mutations in Apc and aberrant Wnt signalling 
in colon cancer. Apc was one of the first genes to be conditionally deleted in the adult intestine. 
Shibata and colleagues proved loss of Apc was sufficient to drive tumourigenesis when they delivered 
AdCre to the colon of mice and observed colonic polyp formation (42). Acute deletion throughout the 
intestine happened some years after this following the development of efficient inducible intestinal cre 
recombinases; AhCre (43,44) and VillinCreER (45). Loss of both copies of Apc led to a rapid 
phenotype now termed a “crypt progenitor-like phenotype” with rapid proliferation and perturbed 
differentiation (44,45) . Importantly, these experiments showed a rapid translocation of β-catenin to 
the nucleus, and activation of Wnt signalling target genes immediately following Apc loss, thus 
supporting the model that Apc loss, and deregulation of WNT signalling, is one of the earliest events 
during tumour initiation. This was supported by experiments in which a mutant form of β-catenin, 
which could not be phosphorylated and targeted for degradation, was expressed under the control of 
the cytokeratin 19 gene to drive expression in the intestine. These mice also developed intestinal 
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tumours, although more readily in the small intestine than the colon, demonstrating that deregulated 
Wnt signalling can lead to tumourigenesis (46).   
The idea that tumourigenesis was a multistep process had been postulated in 1958 (47) and was 
further refined by Weinberg (48) and Vogelstein (49). The classical model for the sequential order of 
mutations in colon cancer proposed mutations in Apc as the initial trigger, followed by mutations in the 
same cell for K-ras, Tgf-β signalling and p53 (50). Compound mutants now enabled researchers to 
functionally investigate this and establish which oncogenes or tumour suppressors co-operated with 
one another. Work from the Taketo lab was the first to show that Min mice with an additional 
heterozygous mutation to the Tgf-β signal transducer Smad4 developed invasive intestinal tumours, 
thus demonstrating that oncogenes and tumour suppressors co-operate to promote tumour 
progression in vivo (51).  
The use of conditional alleles allowed more accurate models of cancer to be generated, thus avoiding 
the embryonic lethality of systemic mutations, which is well illustrated by a series of papers from Alan 
Clarke’s group. They showed that knock-in of the activating mutation of K-ras (LSL-KRASG12V) in the 
intestine did not induce tumourigenesis, but rather accelerated tumour growth and progression after 
Apc had been deleted (52). Interestingly, expression of a different mutant form of Kras in the intestine, 
K-rasG12D, induced tumourigenesis (53). However, only a single tumour was observed in the small 
intestine of 25% of mice aged at least a year, suggesting that additional mutations are required in 
concert with Kras to initiate tumourigenesis. Serrated tumours did develop in the colon of 50% of K-
rasG12D; Ink4a/Arf-/- mice, which allowed K-ras induced senescence to be overcome (53). This 
highlights the use of mice in identifying the context specific nature of oncogenes as in contrast to the 
intestine, the expression of mutant KRAS in the lung rapidly induces multiple adenomas (54). An 
elegant example of how the advent of very specific cre recombinases allowed researchers to 
elucidate the cell of origin of intestinal cancer comes from work examining the function of the tumour 
suppressor Pten. Deletion of Pten specifically in the intestinal epithelium using VillinCreER did not 
induce tumourigenesis, but compound mutant mice in which Apc and Pten were co-deleted resulted in 
invasive adenocarcinoma (55). In contrast, another group observed rapid intestinal tumourigenesis 
when Pten was deleted from the intestine, but this group used the Mx1Cre which drives 
recombination in the epithelium and the stroma, prompting suggestions that stromal loss of Pten was 
important (56). This data strongly suggests that stromal deletion of Pten may give rise to tumours 
within the intestine, a situation similar to what has been shown with LKB1 (57).  However, when mice 
with epithelial specific deletion of Pten were aged (using AhCre to drive recombination), they 
developed intestinal tumours that were histologically consistent with juvenile polyps observed in 
Cowden Syndrome, with expanded mesenchymal compartments and immune infiltrates, which 
progressed to become invasive neoplasias (58). These data suggest that Pten deletion alone can 
trigger intestinal tumourigenesis, albeit with extended latency, and that Pten deficient epithelial cells 
can affect the underlying stromal cells. However, potentially the most efficient system to form tumours 
driven by Pten loss is when there is loss in both the tumour and the surrounding mesenchyme (56). 
This may be similar to the situation in breast cancer where the Leone group have shown elegantly 
that Pten deletion in fibroblasts can drive aggressive breast cancers in mice that much more closely 
resemble that of humans (59).  
These experiments also suggest that the classic sequential order of mutations is not always required 
to induce tumourigenesis. This was illustrated in further experiments from Alan Clarke’s group 
designed to elucidate the co-operation between Apc, Pten and Kras during intestinal tumourigenesis. 
Compound mutant mice in which Apc and Pten were deleted concurrently with an activated KrasG12D 
mutation in the intestinal epithelium resulted in invasive adenocarcinoma (60). Surprisingly, a 
tumourigenic synergy was also revealed between Pten and K-ras, as mice with deleted Pten and 
mutant K-ras, but wild-type for Apc, also developed intestinal tumours (60). These lesions were 
markedly different from the triple mutant tumours however, and instead displayed a spectrum of 
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serrated lesions, which progressed to invasive adenocarcinoma and metastasised to the pancreas, 
liver and lungs in 41% of mice. Pten and K-Ras both activate PI3K, and indeed serrated tumours in 
the double mutant Pten K-ras mice displayed increased PI3K signalling (60). This led to further 
studies investigating PI3K in colon cancer which revealed that deletion of Apc concurrently with 
expression of the PI3K activating mutation found in humans, Pik3caH1047R, resulted in invasive 
intestinal tumours in mice (61).  
p53 (or tumour protein 53, TP53), was amongst the first of the mouse knockouts (62), and developed 
multiple tumour types predominantly sarcomas and lymphomas (63). These studies demonstrated it 
was a “bona fide” tumour suppressor gene. It has since been identified as the gene most frequently 
mutated in all types of cancers, with an estimated 50% of tumours possessing a p53 mutation (64). 
Interestingly, p53-/- mice did not develop intestinal tumours, however ApcMin/+ p53-/- mice had increased 
tumour initiation with an increase in invasive tumours (65), suggesting that p53 mutations are more 
important during later stages of intestinal cancer.  One problem with these studies were that as the 
p53 knockout mouse rapidly succumbed to lymphoma it was difficult to unravel the precise impact on 
intestinal tumourigenesis. Human intestinal tumours also frequently harbour a specific mutation to p53 
(R175H), which was found to possess different properties to Wt p53 and also to deletion of p53. 
Indeed, when Apc was deleted in the intestine with co-expression of p53R172H (the mouse version of 
the human mutation) using AhCre, all mice now developed invasive adenocarcinoma (66). Similarly, 
deletion of exons 2-10 of Tp53 specifically in mouse intestinal enterocytes using VillinCre did not 
induce tumourigenesis until mice were treated with the carcinogen azoxymethane (AOM) which 
causes activating mutations in β-catenin (and hence high wnt pathway) (67). These tumours were 
invasive, and formed in the colon of AOM (due to colonic metabolism of AOM). This overcomes a 
potential problem of the ApcMin  mice in recapitulating human cancer, the preponderance of small 
intestinal tumours though also suggests a similar molecular mechanism regulates tumourigenesis in 
the small intestine and colon (co-operation between deregulated Wnt and p53), and highlights the 
usefulness of carcinogenic models to gain further insight into intestinal cancer. Furthermore, the 
development of colonic specific Cre mice such as Cdx2Cre has enabled researchers to better mimic 
human disease, in which tumours develop predominantly in the colon (68), allowing the study of the 
interaction between colon tumours and the commensal microbiome which is most abundant and 
diverse in the colon.  Indeed deletion of Apc inhibits differentiation of mucus secreting cells (44)  
which has been shown to result in defects in the barrier function of the colonic tumours observed in 
Cdx2CreERT ;Apcflox/flox mice (67) to allow invasion of microbial species (69).  This in turn has been 
shown to induce NF-ĸB activation and increase cyctokine expression to fuel colonic tumour growth 
(69), which is enhanced in tumours with mutant p53 (70) .    
 
Of all the cell signalling pathways, the TGF-β pathway is one where the potential tumour suppressive 
and promoting pathways needed to be tested in vivo to elucidate the functional relevance in cancer. 
Both SMAD4 and TGFBR2 are commonly mutated or inhibited in CRC, though there is compelling 
data to suggest upregulation of TGF-β ligand particularly is stromal fibroblasts may drive by tumour 
progression. Deletion of the TGF-β receptor Tgfbr2 specifically in the intestinal epithelium using 
VillinCre did not induce the formation of tumours, however, co-deletion of Apc and Tgfbr2 in the 
intestine promoted the progression of adenomas (observed after Apc deletion alone) to 
adenocarcinomas (71). However, the same group later showed that Apc mutations are not always 
required to reveal the oncogenic capacity of deregulated Tgf-β signalling, as mice with mutant Kras 
(KrasG12D ) and deletion of Tgfbr2 specifically in the intestine also developed intestinal tumours with 
~15% of them becoming invasive and metastasising to the lymph nodes and/or lungs (72).  This is of 
interest to human CRC as many tumours that have mismatch repair deficiency (approximately 20%) 
do not mutate APC and have mutations in TGFBR2 (due to a microsatellite repeat which is commonly 
mutated) 
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TGF-β has very recently also been identified as a regulator of the serrated neoplasia pathway in the 
intestine (73). Colon cancer is currently classified into four consensus molecular subtypes (CMSs) 
according to several biological parameters including gene expression and molecular aberrations (74). 
Work from JP Mademas lab showed that sessile serrated adenoma organoids carrying BRAFV600E 
mutations respond differently from tubular adenoma organoids when exposed to TGF-β, and acquired 
a mesenchymal phenotype, characteristic of the CMS4 group which has a very poor clinical prognosis 
(73). Indeed work from Eduard Batlle’s group suggests that these mesenchymal expression patterns 
in serrated tumours are due to TGF-β ligand secretion from the stroma, and these may confer the 
poor prognosis of this subtype, (75) suggesting that TGFβ inhibition in this group may be a 
therapeutic strategy (75). Metastatic genetically engineered mouse models (GEMM) of CRC are now 
required more than ever so these treatments can be modelled in an immunocompetent setting. 
One question that remains from alternative models of colon cancer that lack Apc mutation is whether 
they activate Wnt signalling during tumour progression. Allan Bradleys group observed that intestinal 
tumours developed in VillinCre;BrafV637E mice, with Wnt signaling  deregulation observed in very early 
high-grade dysplasia (76). Sequencing revealed that several Wnt regulator genes were mutated in 
these Braf driven lesions, including Apc, suggesting Wnt signalling is important during early dysplasia 
progression (76). In support of this model, most intestinal tumour organoids that are generated 
without Apc mutations are able to grow in a Wnt and R-Spondin (Wnt agonist) independent manner, 
strongly suggestive of mutations somewhere in the Wnt pathway.  Thus it is likely that invasive 
tumours observed in long latency mouse models of cancer have acquired additional mutations to 
genes which drive progression such as Wnt regulators. The continued importance of aberrant Wnt 
signalling in intestinal cancer has recently been shown in a study from Scott Lowes’ lab in which they 
used a doxycycline-regulated shRNA which enabled them to initially inhibit Apc and then conditionally 
re-express it in vivo. Using this system they induced regression, via differentiation of colonic 
adenocarcinomas upon re-expression of Apc, even in tumours harbouring oncogenic mutations to 
Kras and p53 (77). 
Together, the experiments above have given us many novels insights into the molecular events that 
regulate tumour initiation, growth and progression, and provide a roadmap from normal tissue to 
invasive tumour via the oncogenes and tumour suppressor genes involved (Fig. 1). This basic 
understanding of the mechanisms driving cancer are critical to identify therapeutic targets and 
strategies. For a more detailed review of the development of mouse models of intestinal 
carcinogenesis see our recent review (78).   
 
Using mouse models to assess the importance of apoptosis to carcinogenesis 
Mouse models have allowed the study of fundamental processes involved in carcinogenesis. In a 
landmark paper in 1982, David Vaux investigated the role of bcl-2, which had been previously 
identified in patients with follicular lymphoma as being translocated into the immunoglobulin heavy 
chain locus. He discovered that bcl2 did not promote proliferation, but rather prevented the death of 
cells deprived of growth factor, and hypothesised that genes regulating cell survival such as bcl-2 are 
important during transformation (79). This discovery of a new type of oncogene that inhibits cell death 
triggered huge interest into how cell death is regulated and how it might be exploited to treat cancer 
(80).  
The differences between the phenotype of Rb1-/- mice and that of humans with Rb1 mutations 
questioned the validity of using mouse models of human disease. However, subsequent studies to 
reveal the reason for these differences led to substantial increases in our understanding of the 
molecular events behind genotype and phenotype, and inadvertently, that evasion of apoptosis (cell 
death) was a hallmark of cancer. 
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Although originally implicated as a regulator of cell cycle following DNA damage (81,82), it was also 
discovered that p53 regulated cell death (83,84). Indeed, this was able to help explain one of the 
molecular differences between mice and humans with regards to Rb1, as it was elegantly 
demonstrated in compound genetic mutant mice that Rb1-/- cells were deleted in the murine retina via 
p53-dependent apoptosis, thus explaining why Rb1-/- mice did not develop retinoblastoma (85). 
p53 is also required for intestinal crypt cells to induce apoptosis after exposed to gamma irradiation in 
vivo (86), via a mechanism that requires Myc to activate p53 via Mdm2 (87) However, studies in P53 
knockout mice showed that there was not simple correlations between loss of apoptosis, clonogenicity 
and carcinogenesis (88). For example, loss of p53 sensitises mice to radiation despite blocking the 
apoptosis response, and increased p53 in this context can protect mice from radiation induced 
pathologies. Remarkably the reason for this is not understood (89,90).  
Separate studies from the groups of Tyler Jacks and Gerard Evan demonstrated that genetically 
restoring p53 function resulted in regression of lymphomas and sarcomas in mouse models, thus 
providing proof of principal that reactivation of p53 function could be therapeutically attractive for 
treating cancer (91,92) As one of the first genes to be knocked out in mice, p53 has been one of the 
most widely studied and has been implicated in multiple cell functions including apoptosis, 
proliferation, invasion, metabolism and stemness, and interacts with other oncogenes and tumour 
suppressors (93). Consequently, huge efforts had been devoted to generate or identify compounds 
that could restore wild-type activity to mutated p53, and of these APR-246 (PRIMA-1met) (94) was the 
first to be used in clinical trials (95), and is currently in phase Ib/II trials for patients with high-grade 
serous ovarian cancer (96). 
The gp130/Jak/Stat signalling pathway is also frequently deregulated in many cancers, including 
those of the gastrointestinal tract, and thus has attracted research interest into the therapeutic benefit 
of targeting this pathway (97). One of the first experiments using transgenic mice to elucidate the role 
of this pathway in cancer, identified that deletion of Stat3 in the mammary gland blocked apoptosis, 
thus implicating this pathway as a regulator of apoptosis in vivo for the first time (98). More recent 
studies have identified a similar role for Stat3 to regulate cell survival in intestinal tumourigenesis (99), 
highlighting the gp130/Jak/Stat pathway as an attractive target for therapeutic intervention for 
gastrointestinal cancer (100,101). 
The ability to therapeutically induce apoptosis in cancer cells was very challenging, due in part to the 
observation that mutant p53 prevented the induction of pro-apoptotic BH3-only proteins (102). BH3-
only proteins induce apoptosis by inhibiting Bcl2 family proteins, and thus an ingenious way to by-
pass this problem was to mimic the function of BH3-only proteins which was achieved by Feik, 
Rosenberg and co-workers who developed a BH3-only memetic which had potent cell killing 
properties (103). In 2016 the FDA approved the use of a BH3-only memetic (Venclexta [venetoclax]) 
for the treatment of patients with chronic lymphocytic leukemia (CLL). This was the culmination of 28 
years of research, after the original identification of Bcl2 as a regulator of cell death (80), and 
highlights the importance of basic research and how understanding molecular cell biology in vivo, can 
lead directly to translational outcomes to improve patient care.  
 
 
Using mouse models to assess the functional importance of alterations in methylation to 
carcinogenesis 
Epigenetic changes such as methylation act to regulate gene expression whereby methylation of 
regulatory CpG island shores, up to 2 kb away from gene promoter regions, can inhibit transcription 
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(104).  The CpG islands of tumour suppressor gene such as p16 (105) and indeed APC (106) in 
breast cancer are often highly methylated and this correlates with low expression. Global methylation 
was also observed to be frequently reduced (hypomethylated) in tumours (107) and thus an early 
question in the field was to define if this change in methylation was a cause or consequence of 
transformation. The ApcMin/+ mouse served as a useful mouse model to answer this question, with 
compound mutants in which the DNA methyltransferase gene Dnmt1 was also mutated resulted in 
marked decrease in intestinal tumour formation (108,109). These data suggested that methylation 
was an important regulator of tumourigenesis and not merely a non-functional outcome of the 
transformation itself. 
Several subsequent studies have supported this model by investigating the consequences of 
disrupting methylation in mouse models of intestinal cancer. The methyl binding domain (Mbd) 
proteins, which can recognise methylated CpGs and recruit transcriptional repressors, have also been 
shown to influence tumourigenesis, as ApcMin/+ Mbd2-/- mice developed significantly less tumours than 
their ApcMin/+I littermates (110). Similarly, genetic deletion of the DNA methylation-dependant 
transcriptional repressor Kaiso also reduced tumourigenesis in Kaiso deficient ApcMin/+ mice (111). It 
was thus speculated that epigenetic gene silencing that contributes to the cancer phenotype. In 
support of this hypothesis, transcriptome analysis of the intestine of Apc deleted Mbd2-/- mice 
revealed an increase in the transcriptional repressor Lect2, which was subsequently shown to be a 
novel Wnt pathway inhibitor (112). This provided a mechanism by which deficiency of methylation 
attenuates Wnt signalling to reduce intestinal tumourigenesis (112). Indeed, genome-wide analysis of 
promoter DNA methylation in several different cancers, including colon cancer, identified that Wnt 
pathway repressors are frequently regulated by epigenetic mechanisms (113). However, the precise 
role of Wnt target genes and methylation in colon cancer may not be as simple as first predicted as 
some Wnt target genes associated with the cancer stem cell signature such as Lgr5, Ascl2 and Axin2 
become silenced by CpG methylation during tumour progression, and can predict for recurrence free 
survival (114).  
It should be noted that not all Mbd proteins act in a similar fashion to that of Mbd2 described above. 
For example, ApcMin/+; Mbd4-/- mice actually had an increased susceptibility to develop intestinal 
tumours associated with more CpG to TpG mutations in the Apc gene (115).  In addition to its role as 
a thymine glycosylate, Mbd4 has also been shown to interact with the DNA mismatch repair (MMR) 
protein Mlh1 (116), which is able to mediate apoptosis in the intestinal epithelium and potentially 
increase the survival of transformed cells (117).  
Hundreds of genes have altered methylation status in colon cancer and elucidating exactly which of 
these are important during each stage of colon cancer is of continued interest in the field. One of the 
challenges in studying methylation has been establishing a causative link between methylation and 
gene regulation at a single locus. For example the genetic studies to investigate epigenetic regulators 
such as the methyl binding domain proteins result in expression changes to many genes, but cannot 
distinguish which of the changes is important for any observed phenotype without additional 
compound mutations. The development of CRISPR/Cas9 (clustered regularly interspaced short 
palindromic repeats/CRISPR-associated 9) technology (described in further detail in the ‘Organoids 
and CRSPR/Cas9 gene editing’ section below) allows researchers to fuse epigenetic regulatory 
domains such as the acetyletransferase p300 (118) or histone demethylase LSD1 (119) onto mutant 
Cas9 proteins which do not cleave DNA, and thus it is now possible to direct methylation, or 
demethylation to any locus using specific gRNA. Not only is this a powerful research tool, but it also 
presents a potential clinical tool to modify pathological methylation of tumour suppressor genes or 
oncogenes in the future. 
As methylation is considered a hallmark of cancer, another potentially powerful use of understanding 
methylation changes is its use as a biomarker. In recent years, advances in technology have enabled 
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comprehensive genome wide methylome analysis of tumours and matched normal tissue, and panels 
of markers have been identified which could help detect early-stage colon cancer when it is much 
easier to treat (Reviewed in (120). Non-invasive methods of screening for methylation biomarkers are 
also being developed using more accessible samples including blood, urine and faeces (120).  
In addition to its use as a biomarker, methylated DNA is also being analysed to help predict which 
patients will respond to certain treatments. For example, treatment with an anti-EGFR antibody is 
restricted to patients without mutations in KRAS (121), and methylation associated suppression of 
PTEN has also been shown to predict for a lack of benefit from these drugs (122). Thus the 
information gained from the original studies to understand the role of methylation in cancer could lead 
to methylation biomarkers for detection and drug response in the clinic and potentially novel screening 
strategies.    
 
 
Using mouse models to define intestinal stem cells 
Identification and isolation of the intestinal stem cell (ISC) has long been considered key to 
understanding tumourigenesis of the intestine, since they were thought to be the only epithelial cell 
type which persists long enough to accumulate the multiple mutations required for transformation. 
However, the location and identity of ISCs has been a topic of intense research and debate. The most 
popular model as the putative location of intestinal stem cells was originally proposed in 1965 (123), 
and further supported by work from Chris Potten and colleagues, as just above the Paneth cells at +4 
from the base of the crypts (124).  In contrast a second model proposed by Chen and Leblond in 
1974, after they observed a population of slender cells wedged between Paneth cells at the base of 
the crypts which divided once a day called crypt base columnar cells (CBCs) (125). Rudimentary 
lineage tracing showed that 3H-Thymidine retaining cells were originally restricted to CBCs but 
subsequently, radioactive differentiated cells were observed, thus suggesting CBCs could give rise to 
differentiated cells, and that these cells, and not the +4 cells were the intestinal stem cells (125).  
In 2002, Hans Clevers group demonstrated that Wnt signalling was required for the development of 
intestinal crypts, and thus hypothesised Wnt signalling targets may mark the ISC (126). In one of the 
first experiments using cDNA microarrays to assay expression of large sets of genes, they analysed 
data from colon cancer cells with and without active Wnt signalling and mapped these genes back to 
the intestine using in situ hybridisation to see where deregulated genes were expressed in normal 
crypts (127). One of the genes upregulated in their array was leucine-rich-repeat-containing G-
protein-coupled receptor 5, Lgr5 or Gpr49.  Nick Barker generated an Lgr5EGFP- CreERT2 knockin 
mouse in which EGFP was driven from the endogenous promoter of Lgr5, and Cre could be induced 
upon injection of tamoxifen under control of the endogenous Lgr5 regulatory region. He observed 
GFP expression in the CBCs, and was then able to demonstrate that these cells gave rise to all the 
differentiated cells of the intestinal epithelium in long term experiments in which the Lgr5EGFP- CreERT2 
mouse was crossed to the ROSA26LACZLSL mouse to allow genuine lineage tracing in vivo (128). 
This landmark paper transformed the field of stem cell biology and although several other stem cell 
markers for the +4 position have been proposed, including Bmi-1, Lrig1, HopX and mTERT, Lgr5 
remains a robust and convincing stem cell marker in intestinal crypts, although debate still continues 
especially regarding populations of reserve stem cells and the inherent plasticity and interconversion 
of stem cells (reviewed in (129).  
Developing transgenic mice and identifying ISC markers has allowed researchers to gain huge insight 
into the function of this important cell population. An area of great debate in the field was the nature of 
the turn-over and population dynamics of intestinal stem cells in their crypt base niche. There were 
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two models that researchers considered most likely; firstly, that of asymmetrical division, whereby a 
stem cell gives rise to another stem cell and a transit amplifying cell, and secondly, stochastic, neutral 
drift, in which stem cells divide symmetrically and their fates are dependent on environmental factors 
such as their location in the niche relative to Wnt expressing Paneth cells. In 2010, two independent 
studies using fate mapping experiments demonstrated that neutral drift was the more likely of the 2 
models. The Clevers group used the Lgr5Cre R26-Confetti mouse in fate mapping experiments to 
demonstrate that neutral drift was the more likely of the two models (130), whilst the Winton group 
used very low deletion of  a single reporter (in ISC  marker agnostic approach) to reach the same 
conclusion (131). Both groups also suggest similar patterns in adenoma however as yet no-one has 
experimentally examined the nature of stem cells in carcinomas (132). From elegant modelling 
studies in human tumours, a big bang model has been proposed where selection occurs early but 
once tumours are large neutral drift best explains the evolution of tumours (133). 
Given the rapid turnover of the intestine, every 4-5 days, which is driven by continuous and rapid 
proliferation of cells in the transit amplifying zone, just above the crypt base, “reserve” ISC or label 
retaining cells must be able to escape these processes. Paneth cells, which secrete antimicrobial 
peptides and enzymes such as defensin and lysozyme, are located at the base of the crypt between 
the stem cells and therefore seem to escape this upward migration and reside within the intestine for 
many weeks (134). In 2013 the Winton group solved this long-standing question using H2B-YFP to 
identify long term, label retaining cells (LRCs). They found that these slow cycling cells were located 
in the stem cell niche and had a combined secretory and stem cell signature, and over time 
differentiated into Paneth cells (134). Furthermore, LRCs were able to function as a reserve pool of 
stem cells as they were able to contribute to the stem cell pool after crypts were damaged chemically 
or by irradiation (134-136). 
A population of reserve stem cells is also proposed at the +4 position, and marked by one of several 
different markers including Bmi-1 (137), Lrig1 (138) and Hoxp (139). For example, ablation of Lgr5+ 
cells does not perturb intestinal homeostasis (137,140), due to additional cells expressing Bmi-1 (137) 
or Hoxp (139) having the capacity to compensate and subsequently re-express Lgr5. Taken together, 
these experiments demonstrate a high level of plasticity whereby a population of functional adult stem 
cells can be maintained in situations of stress. This plasticity in the intestinal epithelium has most 
likely evolved to enable it to cope with the harsh physical and chemical stresses encountered in the 
gut. For a more detailed review of this area see the recent publication by Snippert and Vermuelen 
(136). 
 
Stem cells, Wnt signalling and intestinal regeneration 
Mouse models have also allowed the investigation of the intestines remarkable capacity to regenerate 
following injury. If it were not for this regenerative function it is unlikely that anyone would survive 
radiotherapy. The canonical Wnt signalling pathway is activated during intestinal regeneration as 
assayed by the presence of nuclear β-catenin and upregulation of Wnt target genes including c-Myc 
(141). Indeed c-Myc was demonstrated to be required for efficient intestinal regeneration, since 
epithelial deletion of c-Myc prior to irradiation resulted in a marked reduction in the number of 
regenerating crypts via a mechanism involving focal adhesion kinase (FAK) and Akt/mTOR (141). C-
Myc was also shown to be critical for stem cell function in the intestinal epithelium, as deletion 
specifically in this tissue using AhCre; c-Mycfl/fl
 mice triggered rapid repopulation of the epithelium in a 
process similar to regeneration, but differing in that the epithelium is not denuded prior to the event 
but rather is triggered via a deleterious event in the stem cells (in this case deletion of c-Myc). This 
process of repopulation is another mechanism to assist the intestinal epithelium to cope with its harsh 
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environment, and was also observed upon deletion of other critical genes including Stat3 (142), Chk1 
(143) and Brg1 (144).  
Lgr5+ cells have been demonstrated to be essential for intestinal regeneration as ablation of Lgr5+ 
cells using Lgr5DTR mice treated with diphtheria toxin completely blocked regeneration following 
irradiation (140). The importance of Wnt signalling during regeneration was functionally demonstrated 
when it was shown that the Wnt receptor Fzd7 was required for efficient regeneration (145). Fzd7 was 
also demonstrated to be the predominant Wnt receptor transmitting Wnt signalling in the Lgr5+ 
intestinal stem cells since deletion was deleterious and triggered repopulation (145). 
The source and requirement for Wnt ligands in the intestine during homeostasis and regeneration is 
still an area of controversy. Hans Clevers’ lab showed that Paneth cells were required for efficient 
establishment of mini-gut organoid cultures, and that they secreted various growth factors including 
Wnt3 (146). The Wnt agonist R-Spondin 1 is also required in the culture medium to culture organoids 
(146). In support of the model whereby Paneth cells supply Wnt ligand for intestinal regeneration, 
Alan Clarke’s group showed that the capacity of the intestinal epithelium to repopulate after deletion 
of β-catenin was severely compromised in the absence of functional Paneth cells resulting in loss of 
intestinal epithelial integrity (147). This supported a previous study from Ricardo Fodde’s group 
showing that Paneth cells lose their differentiated identity after irradiation and can proliferate to 
contribute to regeneration (135). Interestingly, inflammation induced by treating mice with 3% dextran 
sodium sulfate (DSS) was recently shown to promote the secretion of secreted phospholipases A2 
(sPLA2s) in Paneth cells which increased Wnt signalling to regulate stem cell function (148). This 
could provide a possible mechanism for Paneth cells positively regulating regeneration/inflammation 
in the intestine. In contrast to these results, a study from Frederic de Sauvages group observed a 
robust regenerative response in the intestine of Paneth cell deficient Gfi1KI/KI mice, suggesting Paneth 
cells are dispensable for regeneration (140).  
Surprisingly, there was no detectable phenotype when Wnt3 was deleted from the intestine in vivo, 
however, cultured organoids did require Paneth cell-derived Wnt3, suggesting that a mesenchymal 
source of Wnt could compensate for the loss of epithelial Wnt3 (149). Indeed, Wnt2b was able to 
activate Wnt signalling and could restore the growth of intestinal organoids in which Wnt secretion 
was perturbed (149,150). Mice lacking Wnt2b have normal intestinal homeostasis (151), suggesting 
that mesenchymal Wnt2b acts as a safeguard to ensure Wnt ligands can be delivered to the intestinal 
stem cells should Paneth cell-derived Wnt3 be compromised in situations that require the intestine to 
regenerate. This is supported by the observation that Fzd7, the Wnt receptor transmitting Wnt 
signalling in Lgr5+ intestinal stem cells can bind Wnt3 and Wnt2b with equal affinity (145).  Recently it 
has been proposed that Wnt ligands can be secreted in extracellular vesicles by macrophages during 
intestinal regeneration (152), which may also suggest that under different stimuli Wnt secretion from 
different cells can regulate either homeostasis (low Wnt levels expressed from epithelium allowing 
normal differentiation) or regeneration in the intestine (higher Wnt levels expressed from 
macrophages to drive hyperproliferation and repair). 
The biology of the colonic epithelium is slightly different to that of the small intestine, as the colonic 
epithelium does not contain Paneth cells. However, a subset of C-Kit+ goblet cells has been identified 
that are able to support Lgr5+ stem cells by secreting Notch and EGF ligands (153). As organoids 
cultured from the colonic epithelium also require Wnt signalling to grow (150), this suggests a more 
pronounced dependence on mesenchymal Wnts in the colon, which is supported by the observation 
that no Wnt genes are reported to be expressed in the colon epithelium (149).  
The studies above illustrate the importance of Wnt signalling during regeneration and homeostasis of 
the intestine but it is important to recognise that Wnt signalling does not function in isolation, but 
rather interacts with other signalling pathways that are rate limiting for Wnt-induced phenotypes 
including gp130/Jak/Stat (99,100), Robo1/Slit (154) (155), EGFR/Yap (156), Notch (157), mTORC1 
13 
 
(158) and Rac1 (159). These studies and many others highlight the huge complexity and interaction 
between multiple signalling pathways in the intestine. 
 
The cell of origin and cancer stem cells 
The cell of origin for intestinal cancer was unknown at the time when Lgr5 was discovered, and two 
models were the subject of great debate; the bottom-up model which proposed the cell of origin at the 
base of the crypts (160), and the top-down model which proposed the transformation towards the 
luminal surface and spreads down (161). Using the Lgr5CreERT2 mouse to delete Apc specifically in 
Lgr5+ intestinal stem cells, Barker and colleagues observed rapid, widespread tumour initiation 
throughout the intestinal tract (162). Importantly they also observed that deletion of Apc in 
differentiated enterocytes (using low levels of recombination in AhCre Apcfl/fl mice) caused the 
formation of small lesions that rarely went on to form tumours (or if they did it was at long latency), 
thus demonstrating that Lgr5+ stem cells were indeed efficient cells of origin for intestinal cancer 
(162). This paper seemed to have settled the debate in favour of the bottom-up model, however, two 
papers then discovered that transformation could occur in Lgr5-negative cells outside of the crypt 
base stem cell niche, ether in cells with Apc and Kras mutations (163), or those expressing the BMP 
antagonist Gremlin (164).  More recently, the development of a new Cre (carbonic anhydrase), which 
does not induce in colonic stem cells but only in more differentiated cells, confirmed these results in 
the colon (165). Whilst Apc loss alone was unable to cause tumours (only small lesions), if both Apc 
and Kras were mutated mice then developed tumours with a “top down morphology” (165). These 
papers demonstrate that the CBC is not the exclusive cell of origin for all subtypes of colorectal 
cancer, and that the top-down model is also valid.  However it should be remembered that in human 
cancer it would be very rare that 3 alleles would  be lost simultaneously, so the top down model would 
require the first APC mutation in a stem cell to repopulate the crypt (for a more thorough review of this 
area see (166). It is possible that multiple mutations could occur in the same cell at the same time, in 
situations of high cellular stress such as inflammation or during massive chromosomal 
rearrangements (133). Indeed the ‘big bang’ model predicts that driver mutations are all present from 
the beginning of tumourigenesis, however they may not necessarily have been acquired by the same 
cell at the same time, but rather are acquired rapidly in a cell after the first mutation has occurred 
which then results in a large clonal expansion (133).  
The discovery of Lgr5 as an ISC marker also helped contribute to the continuing debate regarding 
cancer stem cells (CSC). CSCs are hypothesised to be a small population of cells that reside within 
the tumour and are responsible for the growth of the tumour, and thus a very attractive target for 
therapeutic intervention. Experiments investigating CSCs using transplantation of sorted cell 
populations in immunodeficient mice are compromised by the culture procedure the cells must 
undergo during the assay. This may skew the outcomes towards a cell population which is 
inadvertently selected for by the process itself (167). Therefore it was important to investigate stem 
cell potential in an autotochronous model without transplantation. This was achieved using the R26-
Confetti mouse, which can express one of four random colours upon recombination. It was 
demonstrated that the progeny of transformed cells could be lineage traced in the tumours of 
Lgr5Cre; Apcfl/fl; R26-Confetti mice as patches of single colour, demonstrating that each patch of the 
tumour (colour) had originated from a single cell (168). Importantly, the R26-confetti mouse retains 
two of its four colours in the confetti allele after recombination, thus allowing for re-tracing upon a 
second injection of tamoxifen, which subsequently showed that only small populations of cells 
recombined to generate a second colour, demonstrating that the rare Lgr5+ cancer stem cells give 
rise to the other cell types present in the tumour (168). It should be noted this study showed that a 
population of cells was acting as stem cells in adenomas but not their functional relevance. 
Furthermore, depletion of Lgr5+ cells in the intestine with diphtheria toxin did not prevent the 
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formation of hyperplastic crypts when Apc was deleted, suggesting that Lgr5+ cells are not required 
for crypt hyperplasia (140). However, the diphtheria toxin depletion of Lgr5+ cells in an established 
intestinal tumour of, for example a Min mouse, has not been published to date and thus the definite 
role of Lgr5+ cancer stem cells has yet to be fully established.  
The experiments above suggest that targeting the cell of origin or cancer stem cells could be an 
attractive strategy for treating colon cancer. Indeed co-deletion of Apc and either Brahma-related 
gene 1 (Brg1) (169) or one allele of Stat3 (100) specifically in intestinal Lgr5+ cells, significantly 
reduced tumourigenesis. Interestingly, the mechanism for these two similar phenotype outcomes was 
different, as Brg1 deficiency attenuated Wnt signalling (169), whilst reduced Stat3 induced 
senescence to reduce tumour growth and initiation even though Wnt signalling remained high (100). 
 
Organoids and CRSPR/Cas9 gene editing 
Using GEMMs has allowed researchers to gain huge insight into the signalling pathways and cell 
biology required for homeostasis, stem cell function and cancer in the intestine. This knowledge 
enabled Hans Clevers’ group to develop a robust technique for the long-term 3D culture of intestinal 
organoids, which shared many of the physiological characteristics of the in vivo epithelium (146,170). 
This very close resemblance to the primary tissue from which they are derived gives organoids a 
distinct advantage over 2D cultured cell lines and to date culture conditions have been published for 
15 different types of tissue from mice and humans (171). 
Importantly, cancer organoids have also been established from humans thus providing a 
physiologically accurate, expandable supply of ex vivo tissue from patients. This type of approach is 
particularly useful to gain rapid knowledge about the transcriptome and genetic and epigenetic 
mutations of a patient’s tumour and also provides the ability to perform high throughput screens of 
drug combinations to determine the most effective treatment for each individual. 
Another exciting potential use for organoids is in regenerative medicine, in which diseased tissue can 
be transplanted with healthy tissue. Indeed, engraftment of orthotopically-transplanted organoids has 
been used to repair damaged tissue in vivo in the intestine (172), pancreas (173) and liver (174). 
CRISPR / Cas9 is the latest technology to be developed to target and manipulate specific sequences 
of DNA (175) or RNA (176), which allows rapid, cheap replacement of mutated genes. This 
represents considerable promise for regenerative medicine in which mutant genes can be replace in 
patient derived cultured organoids, thus generating healthy tissue which can be expanded for 
replacing diseased tissue (171).  
CRISPR/Cas9 was discovered as a mechanism of immunity in bacteria in which the CRISPR 
transcript, crRNA, guides the endonuclease Cas9 to cleave unwanted, invading DNA from a virus or 
plasmid (175). A noncoding trans-activating crRNA (tracrRNA) was found to be required to facilitate 
crRNA to associate with Cas9 and cleave DNA (177). It was subsequently shown that by fusing the 
crRNA and the tracrRNA together, a single guide RNA (sgRNA) could be constructed that contained 
the specific targeting sequence that was able to associate with Cas9 to facilitates site directed gene 
editing (178). Thus, two components are required to target a gene; Cas9, and a sgRNA comprised of 
a gene target sequence of 23 base pair target sequence fused to a tracrRNA. When these are 
introduced into a cell, or indeed a fertilised zygote to generate mutant mice, they form a complex, 
which is guided to the gene of interest by the 23 base pair sequence, and introduce a double strand 
break in the DNA. If disruption of the gene of interest is the goal, then the non-homologous end 
joining (NHEJ) can be allowed to proceed until an error occurs, leaving indels, and subsequent 
disruption of the gene. The introduction of new sequences of DNA is also possible with the addition of 
a donor DNA template during the process, thus allowing much more complex gene editing (175).  
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Further utilisations of CRIPR/Cas9 technology are currently being developed at a rapid pace including 
introduction of epigenetic silencing (118) and even conditional Cas9 (mutated to prevent DNA 
cleavage) mediated gene silencing, and editing, dependant on exposure to blue light (179,180) or 
doxycycline (181). 
CRISPR/Cas9 was recently employed to demonstrate the multistep mechanism of intestinal tumour 
progression in human intestinal organoids, in which combinations of mutations in APC, KRAS, 
SMAD4 and P53 enabled transformed organoids to grow without the addition of stem cell niche 
factors (182). These organoids displayed several characteristics of intestinal tumours including 
chromosomal instability and aneuploidy, and became invasive when xenotransplanted into 
immunocompromised mice, thus demonstrating the considerable power of combining these two 
technologies to provide a fast and cheap way of generating a model of colon cancer in human cells.    
Tumours contain hundreds of mutant genes, and developing accurate animal models of disease will 
probably require that at least 3 to 5 of these genes is mutated. Achieving this using the traditional 
methods of generating mouse mutants will be very expensive and time consuming. However the use 
of CRISPR/Cas9 can significantly speed up this process, as multiple mutations can be introduced into 
a single fertilised zygote and therefore the first generation of mice are already compound mutants, 
thus alleviating expensive, timely cross-breeding to generate the desired genotypes. For a more 
comprehensive review of CRISPR/Cas9 technology please see (175).   
The expandable nature of organoids provides a large supply of tissue for use in regenerative 
medicine, and high throughput assays for drug discovery and drug combination screens. However, as 
organoids do not contain any stroma or immune components, there are limitations to what can be 
accurately modelled in this system to date (171). This is particularly frustrating with regards to the 
current advances being made with immune checkpoint inhibitors as they cannot be tested in 
organoids. Similarly, patient derived xenografts (PDXs) are a very useful platform to study the 
response of fresh human tumour tissue to novel therapies, especially in cancers that are very 
heterogeneous such as breast, ovarian and gastric cancer. However, PDXs are performed in 
immunocompromised mice, which again prevents analysis of the host immune system during therapy. 
Animal models therefore remain the most accurate way of simulating disease, allowing analysis from 
tumour initiation through to metastasis, and with the advent of CRISPR/Cas9 to allow cheap 
generation of compound mutants, including inducible compound mutants, the use of animal models of 
disease is entering a new and exciting phase. Indeed, very recent work has used CRISPR/Cas to 
mutate Apc, Kras and Trp53 in colonic organoids which developed invasive tumours after orthotopic, 
syngeneic transplantation into the mouse colon using a modified colonoscope, suggesting the next 
stage of in vivo mouse models has begun (183,184) 
   
Conclusion 
Animal models of disease, particularly intestinal cancer, offer significant advantages over the in vitro 
and ex vivo technologies that have been developed and refined in the last decade some of which are 
described above. Recent research has begun to uncover the intimate relationship between the 
biology of the intestine and its resident commensal microbiome, suggesting it also plays an important 
role during colon cancer. Animal models have again been employed to gain insight into this 
interaction which is more challenging to accurately model in vitro. Thus with the development of 
mouse models of colon cancer that are immune-proficient, develop invasive tumours in the correct 
anatomical site as the human disease (colon) and contain a commensal microbiome, researchers 
have developed very accurate pre-clinical models of colon cancer. 
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The massive increase in our understanding of cancer biology in the past 20 years could not have 
been achieved without the ground-breaking discoveries and advances in technology accomplished by 
some of the talented scientists mentioned above. This review has described the events that led to the 
first animal models of disease, the first conditional gene manipulation in vivo, the use of these models 
to elucidate cancer biology, and finally the exciting developments in utilising CRISPR/Cas9 for 
cheaper, faster and potentially more complex gene editing in vivo. Inserting new DNA using 
CRISPR/Cas9 still utilises the homologous recombination strategies discovered by the pioneers of 
generating mutant mice, and thus the skills and techniques they developed, for example to design 
targeting vectors, are still relevant and critical today. 
Of those involved in these field-changing advances, we would like to highlight the contributions made 
by the late Professor Alan Clarke who was a pioneer in the very early use of genetic engineering to 
make mutant mice, and was involved in the very first successful gene-targeted Hprt mutant mouse, 
and first author on the subsequent Nature publications generating the p53 and Rb1 mutants. Alan 
was also at the forefront of the use of these mice to help broaden our understanding of disease and 
the biology of several organs, and was the first to identify the regulation of apoptosis by p53, 
demonstrated that loss of Apc activated Wnt signalling to trigger intestinal tumourigenesis, showed 
the role of methylation regulating genes during intestinal cancer and characterised the genetic co-
operation between many oncogenes and tumour suppressor genes in vivo. Alan’s contribution to the 
field of cancer biology can thus be considered in the highest echelons of scientists past and present, 
and his findings will continue to help shape the field as it progresses.  
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TABLE AND FIGURES LEGENDS 
Figure 1. Venn diagram illustrating in vivo co-operation between mutations in the mouse intestine as 
determined by the phenotype of compound mutant mice. Adeno-CA: Adenocarcinoma. n.d.: Not 
determined. Numbers indicate publication of phenotype as listed in the references. 
 
 
